send mail to firstname.lastname@example.org mentioning your email id and mobileno registered with us! if details not recieved
Resend Opt after 60 Sec.
Please verify your mobile number
Subscribe to Notifications
Stay updated with the latest Current affairs and other important updates regarding video Lectures, Test Schedules, live sessions etc..
Refer & Earn
My Abhipedia Earning
Kindly Login to view your earning
On December 17, 2021, World Health Organisation (WHO) gave approval for emergency use of Covovax vaccine for Children.
Recently, CEO of SII, Adar Poonawalla, announced that SII has planned to launch a COVID-19 vaccine called Covovax for children in next six months. He noted that, this vaccine is under trial and it would offer protection to children aged three years and more.
WHO approved Covovax after it was assessed under its emergency use listing (EUL) procedure on the basis of review of data on quality, safety & efficacy, a programmatic suitability, risk management plan, and manufacturing site inspections which is carried by the Drugs Controller General of India.
Novavax COVID-19 vaccine is sold under the brand name Nuvaxovid and Covovax. This subunit COVID-19 vaccine has been developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). Vaccine is undergoing trials in India under the brand name Covovax. It is stable at 2 to 8 °C.
By: Brijesh Kumar ProfileResourcesReport error
Access to prime resources